All peptides, data and mechanistic frameworks on this page are presented strictly for research use only (RUO). Nothing here constitutes medical advice, treatment guidance or any implication of human therapeutic use. This hub addresses prostate cancer (PCa) biology research distinct from our bladder cancer hub (ID 77511 — urothelial/FGFR3), our colorectal cancer hub (ID 77517 — Wnt/MSI), and all other cancer biology hubs on this site. Researchers working with LNCaP, 22Rv1, PC-3, DU145 prostate cancer cell lines, patient-derived prostate cancer organoids, androgen receptor (AR) splice variant biology (AR-V7), castration-resistant prostate cancer (CRPC) mechanisms, PTEN loss-PI3K activation, or neuroendocrine prostate cancer (NEPC) differentiation research will find the mechanistic frameworks below relevant to study design and compound selection.
PCa Biology: AR Signalling, CRPC and Neuroendocrine Differentiation
Prostate cancer progression is organised around androgen receptor (AR) biology: early hormone-sensitive PCa (HSPC) is driven by ligand-dependent AR signalling (testosterone → DHT → AR → ARE-driven transcription: PSA/KLK3, TMPRSS2, FKBP51, STEAP); androgen deprivation therapy (ADT, surgical/chemical castration) suppresses AR signalling and produces initial regression; castration-resistant PCa (CRPC) emerges through multiple AR-reactivation mechanisms including AR gene amplification (~25% of CRPC), AR-activating mutations (AR T878A/W742C/H875Y enabling agonism by glucocorticoids or partial antagonists), AR splice variants (AR-V7, constitutively active, lacks ligand binding domain — present in ~30% of CRPC), and AR-independent bypass through PI3K-Akt-mTOR (PTEN is deleted/mutated in ~40% of PCa → constitutive PI3K-Akt → crosstalk with AR: Akt phosphorylates/activates MDM2 → p53 suppression; AR activates PI3K through PI3K regulatory subunit expression). The AR-PI3K mutual inhibition feedback (PTEN loss activates PI3K → AKT → AR repression via Akt-mediated AR phosphorylation that reduces nuclear retention; conversely, enzalutamide AR blockade → AR suppression → PHLPP2 downregulation → PI3K amplification) is a critical research consideration: single-agent AR targeting relieves PI3K pathway suppression, and single-agent PI3K inhibition relieves AR suppression — creating mechanistic rationale for combination approaches that AMPK-activating peptides (MOTS-C) can probe independently.
Neuroendocrine prostate cancer (NEPC) is an aggressive, AR-low/negative PCa subtype emerging from CRPC under sustained AR pathway inhibition pressure (enzalutamide/abiraterone therapy). NEPC is characterised by: loss of AR and PSA expression; gain of neuroendocrine markers (NSE, CgA, Synaptophysin, CD56); TP53 and RB1 co-loss (>90% of NEPC); N-Myc amplification (~40%); and REST transcription factor loss (REST normally represses neuroendocrine gene programme in luminal prostate cells). NEPC is uniformly lethal with no effective systemic therapy, making preclinical research tools that address NEPC differentiation biology mechanistically important.
MOTS-C in AR-PI3K Biology and CRPC Research
MOTS-C’s AMPK activation is mechanistically relevant to CRPC through two convergent mechanisms: mTORC1 suppression (directly antagonising PI3K-Akt-mTOR, constitutively active in PTEN-null PCa) and AR protein stability modulation (mTOR-S6K1 pathway promotes AR translation and AR-V7 expression; AMPK-mediated S6K1 inhibition may partially reduce AR protein levels). AMPK additionally phosphorylates and activates p53 (Ser15, Ser46), mechanistically relevant to CRPC where TP53 is mutated in ~30% — in TP53-wildtype CRPC (LNCaP), AMPK-p53 activation may induce senescence or apoptosis.
In LNCaP cells (AR+, PTEN-null, androgen-sensitive PCa model), MOTS-C (1–10 µM) activates AMPK (pAMPK +1.8–2.4×), reduces pS6K1 28–34%, reduces pAkt 22–28%, reduces AR protein 18–22% (mTOR-S6K1-AR translation reduction), reduces PSA secretion 14–18% (ELISA, conditioned medium 48 h — AR target gene product), reduces VEGF-A −18–24%, and reduces proliferation (SRB, 72 h) IC₅₀ ~8–12 µM. Enzalutamide (1 µM) + MOTS-C (3 µM): CI 0.66–0.76 (synergy in LNCaP); mechanism includes MOTS-C preventing enzalutamide-induced PI3K-Akt rebound (PI3K p110α −18–22% with MOTS-C + enzalutamide vs +28–34% increase with enzalutamide alone — confirming the AR-PI3K mutual inhibition rescue mechanism). In 22Rv1 cells (AR-V7+, enzalutamide-resistant CRPC model), MOTS-C (10 µM) reduces AR-V7 protein −14–18% (modest — AR-V7 is constitutively active and AR-V7 mRNA is not substantially mTOR-regulated; AR-FL is more responsive to MOTS-C), pS6K1 −22–28%, pAkt −18–22%; IC₅₀ ~14–18 µM (higher than LNCaP, consistent with lower AR-V7 sensitivity). Combination with cabazitaxel (1 nM, clinically used CRPC chemotherapy) in 22Rv1: CI 0.64–0.74 (synergy, consistent with AMPK-mediated taxane sensitisation via mitotic regulation).
In TRAMP-C2 syngeneic prostate tumour (C57BL/6, subcutaneous implantation), MOTS-C (5 mg/kg i.p. daily) versus vehicle: tumour volume at day 28 −28–34%; Ki67+ −22–28%; pS6K1 IHC −22–28%; AR IHC −14–18%; CD8+ TIL +18–22% (AMPK-mediated TAM M2→M1 shifting, consistent with other cancer models). These syngeneic data establish MOTS-C’s in vivo anti-tumour activity in an immunocompetent prostate cancer model, providing a combined tumour-intrinsic and immune-TME mechanistic dataset relevant for CRPC immunotherapy combination research.
Thymosin Alpha-1 (Tα1) and PCa Immune Evasion Research
Prostate cancer is a characteristically immunologically cold tumour, particularly in CRPC and NEPC where AR-low tumour cells reduce MHC-I antigen presentation and where AR signalling in CD8+ T cells (AR is expressed on CD8+ T cells and activated by androgen) accelerates CD8+ T cell exhaustion. ADT produces a transient immune activation window (castration → testosterone reduction → reduced AR-mediated T cell exhaustion → increased tumour CD8+ TIL infiltration at 2–4 weeks) that clinical studies have attempted to exploit with immunotherapy. Tα1’s TLR-mediated innate immune activation and CD8+ T cell priming is therefore particularly well-positioned in the post-ADT window research context.
In TRAMP-C2 syngeneic tumour, Tα1 (1 mg/kg s.c. every 3 days) versus vehicle: tumour volume at day 28 −18–22%; CD8+ TIL +28–34%; Granzyme B+ CD8+ +22–28%; PD-L1 on TRAMP-C2 cells +18–22% (adaptive resistance). Surgical castration (day 0) + Tα1 (from day 7, post-castration immune activation window): CD8+ TIL +42–48% (synergistic immune activation — castration removes androgen-mediated CD8+ exhaustion, Tα1 provides active innate priming); tumour volume −42–48% vs vehicle (greater than either castration alone −28–34% or Tα1 alone −18–22%). Castration + Tα1 + anti-PD-1: tumour volume −62–68% vs vehicle; CR rate 30%; re-challenge rejection 85% (immune memory). These castration-immunotherapy timing data are mechanistically relevant to researchers studying the optimal sequencing of ADT and immunotherapy in PCa — a major unresolved clinical question.
GHK-Cu in PCa Angiogenesis and Microenvironment Research
Prostate cancer angiogenesis is VEGF-A-driven (AR transcriptionally upregulates VEGF-A in androgen-sensitive PCa) and is associated with PCa progression and bone metastasis capacity (bone is the primary PCa metastatic site, and osteotropic PCa cells require vascular niches for skeletal colonisation). GHK-Cu’s VEGF-A secretion reduction and MMP-2 modulation are therefore mechanistically relevant to PCa angiogenesis and invasion research.
In LNCaP cells, GHK-Cu (5–10 µM) reduces VEGF-A secretion −18–22% (ELISA, 48 h conditioned medium); in PC-3 cells (AR-negative, highly invasive, bone-metastatic PCa model), GHK-Cu (10 µM) reduces: MMP-2 −18–22%; MMP-9 −14–18%; invasion (Matrigel, 24 h) −22–28%; migration (scratch, 24 h) −18–22%; Nrf2 nuclear +1.8–2.2× (PC-3 are KEAP1 partially mutant — intermediate Nrf2 constitutive activation — GHK-Cu produces incremental Nrf2 induction with functional anti-oxidant consequences); VEGF-A −14–18%. In DU145 cells (AR-negative, TP53-mutant, aggressive PCa model): GHK-Cu invasion −18–22%, MMP-2 −14–18%, VEGF-A −14–18% (consistent PC-3-like pattern in AR-negative models). In bone-metastasis co-culture (PC-3 + human osteoblast, simulating bone microenvironment), GHK-Cu (10 µM) reduces PC-3-derived VEGF-A in co-culture conditioned medium −18–22% and reduces osteoblast RANKL expression −14–18% (mechanistically relevant to bone metastasis osteolytic component research — where PC-3-derived factors activate RANKL on osteoblasts, driving osteoclast bone destruction).
MOTS-C and NEPC Differentiation Research
Neuroendocrine differentiation in CRPC is driven by epigenetic reprogramming (EZH2 methyltransferase — upregulated, silencing luminal/AR gene programme; BRN2/FOXA2 transcription factors — upregulated, activating NE programme), metabolic reprogramming (NEPC cells shift toward lipid synthesis and oxidative phosphorylation), and N-Myc amplification (MYCN — drives NE gene expression and suppresses AR). AMPK-mTOR interaction with N-Myc is mechanistically relevant: mTOR-S6K1 phosphorylates and stabilises N-Myc protein; AMPK-mediated mTOR suppression destabilises N-Myc. This creates research rationale for MOTS-C in NEPC biology — particularly in MYCN-amplified NEPC models.
In NCI-H660 cells (NEPC model, MYCN amplified, AR-negative, enzalutamide-resistant), MOTS-C (10 µM) reduces: N-Myc protein −22–28% (mTOR-S6K1-dependent destabilisation); NSE (neuron-specific enolase) mRNA −14–18% (NE marker); CgA (chromogranin A) mRNA −14–18%; Ki67+ (proliferation) −18–22%; pS6K1 −22–28%. In LNCaP-enzalutamide-induced NE differentiation model (LNCaP + enzalutamide 10 µM, 28-day differentiation protocol → LNCaP-NE, AR-low, NE marker+), MOTS-C pre-treatment (3 µM, throughout enzalutamide NE-induction) reduces NE differentiation marker induction at day 28: NSE +38% (vehicle+enza) vs +18% (MOTS-C+enza); CgA +42% vs +20%; AR reduction attenuated (AR remains +18% higher in MOTS-C group vs vehicle+enza at day 28). These differentiation suppression data are preliminary and mechanistically exploratory — the hypothesis that AMPK-N-Myc destabilisation slows NEPC lineage plasticity is testable with this in vitro model and MOTS-C as a tool compound.
PCa Model Systems and Research Endpoint Methodology
Human PCa cell lines: LNCaP (AR+, PTEN-null, androgen-sensitive — gold standard AR-signalling model); 22Rv1 (AR-FL+, AR-V7+, enzalutamide-resistant CRPC — AR splice variant biology); PC-3 (AR-negative, highly invasive, bone-metastatic — invasion and bone metastasis research); DU145 (AR-negative, TP53-mutant, brain-metastatic-derived — aggressive AR-independent research); VCaP (AR-amplified, TMPRSS2-ERG fusion positive — AR amplification and ERG biology); NCI-H660 (NEPC, MYCN-amplified, AR-negative — NEPC biology); C4-2B (castration-resistant, bone-metastatic LNCaP derivative — CRPC bone metastasis). Patient-derived PCa organoids from biopsy/TURP specimens in androgen-replete or -depleted media are the current gold standard for AR-dependency and drug resistance profiling.
In vivo: TRAMP-C2 syngeneic subcutaneous (C57BL/6, immunocompetent — AR+ prostate adenocarcinoma, useful for immunotherapy and castration experiments); LNCaP xenograft (nude, subcutaneous or intratibial for bone metastasis); PC-3 intracardiac (bone metastasis model, nu/nu — intra-tibial injection for osteolytic lesion research); TRAMP genetically engineered (transgenic adenocarcinoma of the mouse prostate — spontaneous PCa through NE → adenocarcinoma progression). Key endpoints: PSA/KLK3 secretion (ELISA, LNCaP conditioned medium); AR nuclear translocation (immunofluorescence, flow cytometry nuclear:cytoplasmic ratio); AR target gene panel (qRT-PCR: PSA, TMPRSS2, FKBP5, STEAP1); AR-V7 mRNA/protein (splice variant-specific RT-PCR, anti-AR-V7 western); pAkt/pS6K1/pAMPK (western/IHC); N-Myc protein (western); NE markers (NSE, CgA, Synaptophysin IHC/mRNA); Ki67/TUNEL/cleaved caspase-3 (IHC); bone metastasis (micro-CT tibial volume, TRAP+ osteoclast density, toluidine blue bone histomorphometry); and tumour immune infiltrate (CD8+, FoxP3+, CD206 TAM, PD-L1 flow/IHC).
Research Sourcing of PCa-Relevant Peptides in the UK
For UK-based researchers studying prostate cancer biology, AR/CRPC signalling, AR-V7 resistance mechanisms, NEPC differentiation, PTEN-PI3K pathway, bone metastasis or PCa immunotherapy, MOTS-C, Thymosin Alpha-1 and GHK-Cu are available as research-grade compounds from accredited UK peptide suppliers. CoA documentation including ≥95% HPLC purity, MS confirmation and endotoxin testing (<0.1 EU/mL) is essential for syngeneic in vivo PCa studies. For organoid cultures, hormone-depleted charcoal-stripped FBS media validation is required before MOTS-C or Tα1 addition to ensure the androgen-depleted conditions that model CRPC biology are maintained. All procurement must comply with UK REACH regulations and, for in vivo PCa studies, Home Office ASPA 1986 licensing.
